Viorel Sima / Shutterstock.com
Pharmaceutical company Eli Lilly has reported that its US revenue in 2014 dipped by 29% compared to the previous year, laying the blame on key patents, including those for Cymbalta (duloxetine hydrochloride) and Evista (raloxifene hydrochloride), expiring.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Cymbalta, Evista, patent expiries, results
